Exploring Key Insights from the PAPILLON Trial

A clinical pharmacy specialist examines treatment strategies for EGFR exon 20 insertion mutations, referencing data from the PAPILLON trial, and addresses the challenges associated with managing brain metastases in this patient population.

EP: 1.Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

EP: 2.Examining Key Data from the FLAURA2 and MIRAPOSA Trials

EP: 3.Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

Now Viewing

EP: 4.Exploring Key Insights from the PAPILLON Trial

EP: 5.Common Adverse Reactions to EGFR Therapy

EP: 6.Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

EP: 7.Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

Amivantamab (used with or without chemotherapy, depending on the treatment stage) stands out as the sole recommended treatment for EGFR exon 20 insertion mutations. Its front-line use is supported by the PAPILLON study. What was this study’s methodology?
What were the key results of PAPILLON in terms of both efficacy and safety?
How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?